Skip navigation

Niven R. Narain, Ph.D.

Dr. Niven R. Narain is Co-Founder, President & CEO of Berg, a Boston-based biopharma driving next generation drug and diagnostic development by combining patient-driven biology and Bayesian AI. He is a pioneer in technology development at the intersection of Biology and AI and is inventor of the Interrogative Biology® platform that has unraveled actionable disease insight leading to both de novo and repurposed development of a deep pipeline of products in oncology, metabolic, rare, and CNS diseases, namely BPM 31510 currently in Phase 2 trials for cancer covered by over 650 issued and pending US and international patents.

Dr. Narain is a member of the NASA/Gene Lab Steering Committee, Advisor to US Department of Defense leadership on breast and prostate cancer and forged strategic partners with industry, academia, and US and UK governments. He serves on the Advisory Board of Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School and the Healthy Aging Initiative Commission at No. 10 for the UK Prime Minister. He is an industry thought leader in precision medicine, drug development, and AI/ML serving as a frequent speaker at Economist, Bloomberg, Financial Times, Wired, and Aspen Ideas and many international meetings on medicine and technology.

Boston Business Journal top 40 leaders under 40

Dr. Narain was named to the Boston Business Journal top 40 leaders under 40 (2014), EY Entrepreneur of Year finalist (2018) and to the Deep Knowledge Analytics Top 100 AI Pioneers in Drug Discovery and Advanced Healthcare (2019).

Dr. Narain has been featured on CNN, BBC, CNBC, Forbes, Fox Business, and the Wall Street Journal.

Dr. Narain obtained a BS in Biological Sciences/Philosophy from St. John’s University, NY and a Ph.D. in Clinical Biochemistry with focus on Cancer Biology at the University of Miami Miller School of Medicine where he also did clinical research training in Cutaneous Oncology in the Dermatology and Cutaneous Surgery later serving as Director of Cutaneous Oncology Research. He has published in Nature Medicine and Cell with leading collaborators from academia, NIH, and DoD.

Dr. Narain is most passionate about improving patient care and enabling increased access to innovative medicines towards improved healthcare outcomes.  He is very active in educational programs for STEM programs in Massachusetts and an active leader at the Trinity Episcopal Church Boston participating in numerous mission trips to the Caribbean.